125 related articles for article (PubMed ID: 23127721)
1. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
Gómez Sánchez MA
Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
[No Abstract] [Full Text] [Related]
2. Reply to letter to the editor "infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin".
López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Escribano P
Arch Bronconeumol; 2013 May; 49(5):217-8. PubMed ID: 23218502
[No Abstract] [Full Text] [Related]
3. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.
López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Barrios E; Vicente-Hernández M; Aguado JM; Escribano P
Arch Bronconeumol; 2012 Dec; 48(12):443-7. PubMed ID: 22858303
[TBL] [Abstract][Full Text] [Related]
4. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
Shapiro S; Hill NS
Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
[No Abstract] [Full Text] [Related]
5. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
[No Abstract] [Full Text] [Related]
6. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
LeVarge BL; Channick RN
Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
Humbert M; Maître S; Capron F; Rain B; Musset D; Simonneau G
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1681-5. PubMed ID: 9603154
[TBL] [Abstract][Full Text] [Related]
8. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
Bakst AE; Gaine SP; Rubin LJ
Chest; 1999 Oct; 116(4):1127-9. PubMed ID: 10531185
[TBL] [Abstract][Full Text] [Related]
9. Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
Lawhorn S; Lawhorn CD; Davison C
J Heart Lung Transplant; 1997 Apr; 16(4):472-3. PubMed ID: 9154961
[No Abstract] [Full Text] [Related]
10. Bloodstream infections due to Micrococcus spp and intravenous epoprostenol.
Valdivia-Arenas MA
Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1237. PubMed ID: 19888847
[No Abstract] [Full Text] [Related]
11. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension.
Rich JD; Glassner C; Wade M; Coslet S; Arneson C; Doran A; Gomberg-Maitland M
Chest; 2012 Jan; 141(1):36-42. PubMed ID: 21659437
[TBL] [Abstract][Full Text] [Related]
12. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
[TBL] [Abstract][Full Text] [Related]
13. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
[TBL] [Abstract][Full Text] [Related]
14. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives.
Bratel T; Lagerstrand L; Brodin LA; Nowak J; Randmaa I
Chest; 2005 Dec; 128(6 Suppl):615S-616S. PubMed ID: 16373868
[No Abstract] [Full Text] [Related]
15. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
17. [Pulmonary arterial hypertension treated with prostacyclin or calcium blockers].
Andreassen AK; Geiran O; Madsen S; Hognestad A; Simonsen S
Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3393-6. PubMed ID: 14713978
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
[TBL] [Abstract][Full Text] [Related]
19. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
Stricker H; Domenighetti G; Fiori G; Mombelli G
Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
[TBL] [Abstract][Full Text] [Related]
20. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
Reddy MT; Patel H; Ventura HO
Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
[No Abstract] [Full Text] [Related]
[Next] [New Search]
